brand logo

MEERA SUNDER, MD, Department of Family Medicine, Cambridge Health Alliance, Somerville, Massachusetts

Am Fam Physician. 2022;106(1):91-92

Author disclosure: No relevant financial relationships.

Abametapir 0.74% (Xeglyze) is a topical ovicidal pediculicide labeled for the treatment of head lice infestation in patients six months and older.1,2

DrugDosageDose formCost of full course
Abametapir (Xeglyze)One application to head and scalp for 10 minutes0.74% lotionPrice not yet available

Safety

No serious adverse effects were observed in patients receiving abametapir in premarketing trials. Safety has been established in patients six months and older.1,3 Abametapir is not recommended in patients younger than six months because of a potential risk of increased systemic absorption and adverse effects caused by the inactive ingredient, benzyl alcohol. No data are available on the use of abametapir in pregnant or breastfeeding patients.1

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Continue Reading

More in AFP

More in PubMed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.

Copyright © 2024 American Academy of Family Physicians. All Rights Reserved.